Fujimoto Naohiro
   Department   School of Medicine  Urology, Clinical Medical Sciences
Article types article
Language English
Peer review Non peer reviewed
Title Definitive 3D-CRT for clinically localized prostate cancer: modifications of the clinical target volume following a prostate MRI and the clinical benefits.
Journal Formal name:SpringerPlus
Domestic / ForeginForegin
Volume, Issue, Page 4,347頁
Author and coauthor Yamaguchi Shinsaku, Ohguri Takayuki, Fujii Masami, Yahara Katsuya, Hayashida Yoshiko, Fujimoto Naohiro, Korogi Yukunori
Publication date 2015
Summary PURPOSE:To evaluate the modifications of the tumor stage and clinical target volume following a prostate magnetic resonance imaging (MRI) to evaluate the tumor (T) staging, and the clinical benefits for prostate cancer.METHODS:A total of 410 patients with newly diagnosed and clinically localized prostate cancer were retrospectively analyzed. The patients were treated with definitive three-dimensional conformal radiotherapy (3D-CRT). In all of the patients, digital rectal examination, transrectal ultrasound, prostate biopsy and computed tomography were performed to evaluate the clinical stage. Of the 410 patients, 189 patients had undergone a prostate MRI study to evaluate the T staging, and 221 patients had not.RESULTS:Modification of the T stage after the prostate MRI was seen in 39 (25%) of the 157 evaluable patients, and a modification of the risk group was made in 14 (9%) patients. Eventually, a modification of the CTV in 3D-CRT planning was made in 13 (8%) patients, and 10 of these had extracapsular disease. Most of the other modifications of the T staging were associated with intracapsular lesions of prostate cancer which did not change the CTV. There were no significant differences in the biological relapse-free survival between the patients with and without a prostate MRI study.CONCLUSIONS:Modification of the CTV were recognized in only 8% of the patients, most of whom had extracapsular disease, although that of the T stage was seen in approximately one-quarter of the patients. Prostate MRI should only be selected for patients with a high probability of extracapsular involvement.
DOI 10.1186/s40064-015-1138-9
PMID 26191474